OnKure Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
OKUR$3.19+11.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $151,443 | $59,050 |
| Marketable securities, available for sale | 11,862 | — |
| Prepaid expenses and other current assets | 2,288 | 1,789 |
| Total current assets | 165,593 | 60,839 |
| Property and equipment, net | 414 | 618 |
| Operating lease right-of-use asset | 661 | 387 |
| Other assets | 409 | 273 |
| Total assets | $167,077 | $62,117 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,309 | $1,433 |
| Accrued expenses and other current liabilities | 6,229 | 3,939 |
| Operating lease liabilities, current portion | 251 | 549 |
| Total current liabilities | 8,789 | 5,921 |
| Long-term operating lease liabilities | 539 | — |
| Other long-term liabilities | 12 | 12 |
| Total liabilities | 9,340 | 5,933 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Common stock, Class A, $0.0001 par value; 200,000,000 shares authorized; 40,503,094 and 13,673,565 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 4 | 1 |
| Common stock, Class B, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2026 and December 31, 2025 | — | — |
| Additional paid-in capital | 420,353 | 270,424 |
| Accumulated other comprehensive loss | (30) | — |
| Accumulated deficit | (262,590) | (214,241) |
| Total stockholders’ equity | 157,737 | 56,184 |
| Total liabilities and stockholders’ equity | $167,077 | $62,117 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.